Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shareholders (or potential shareholders) will be happy to see that the Co-Founder, Richard Miller, recently bought a whopping US$1m worth of stock, at a price of US$1.73. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 39%.

See our latest analysis for Corvus Pharmaceuticals

Corvus Pharmaceuticals Insider Transactions Over The Last Year

Notably, that recent purchase by Richard Miller is the biggest insider purchase of Corvus Pharmaceuticals shares that we've seen in the last year. Even though the purchase was made at a significantly lower price than the recent price (US$2.03), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

In the last twelve months Corvus Pharmaceuticals insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Corvus Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership Of Corvus Pharmaceuticals

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Corvus Pharmaceuticals insiders own 3.9% of the company, worth about US$3.8m. I generally like to see higher levels of ownership.

So What Does This Data Suggest About Corvus Pharmaceuticals Insiders?

The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Corvus Pharmaceuticals insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, Corvus Pharmaceuticals has 6 warning signs (and 2 which are concerning) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.